Our key goal is to demonstrate in vivo transformation of siRNA in the cell using our novel cyclic peptide platform. This will initially happen through:

• Our partnership and collaboration with pharmaceutical companies that are facing challenges with the delivery of their compounds, including siRNA

• Providing our proven technology platform to companies who have an interest in our platform.